Oppenheimer Asset Management Inc. Has $385,000 Stock Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Oppenheimer Asset Management Inc. reduced its stake in Bausch Health Companies Inc. (NYSE:BHCGet Rating) by 13.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,030 shares of the company’s stock after selling 6,850 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Bausch Health Companies were worth $385,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Blueshift Asset Management LLC acquired a new position in shares of Bausch Health Companies in the first quarter valued at approximately $464,000. Metis Global Partners LLC acquired a new position in Bausch Health Companies in the 1st quarter valued at $254,000. Assetmark Inc. increased its position in Bausch Health Companies by 454.3% during the 2nd quarter. Assetmark Inc. now owns 10,421 shares of the company’s stock worth $87,000 after buying an additional 8,541 shares during the period. Woodline Partners LP lifted its holdings in shares of Bausch Health Companies by 1.1% during the first quarter. Woodline Partners LP now owns 1,013,462 shares of the company’s stock worth $23,158,000 after buying an additional 10,944 shares in the last quarter. Finally, Guardian Capital Advisors LP boosted its position in shares of Bausch Health Companies by 73.8% in the first quarter. Guardian Capital Advisors LP now owns 63,690 shares of the company’s stock valued at $1,447,000 after acquiring an additional 27,040 shares during the period. 70.07% of the stock is owned by institutional investors.

Bausch Health Companies Stock Performance

NYSE:BHC opened at $6.97 on Thursday. Bausch Health Companies Inc. has a twelve month low of $4.00 and a twelve month high of $28.35. The company has a quick ratio of 0.77, a current ratio of 1.05 and a debt-to-equity ratio of 48.05. The stock’s 50-day simple moving average is $7.01 and its 200 day simple moving average is $7.90. The firm has a market capitalization of $2.52 billion, a PE ratio of 9.96, a price-to-earnings-growth ratio of 0.13 and a beta of 0.99.

Wall Street Analysts Forecast Growth

BHC has been the topic of a number of recent research reports. JPMorgan Chase & Co. lowered shares of Bausch Health Companies from an “overweight” rating to a “neutral” rating in a research report on Thursday, July 28th. Royal Bank of Canada boosted their price target on Bausch Health Companies from $4.50 to $8.00 and gave the company a “sector perform” rating in a research note on Thursday, September 1st. Piper Sandler lowered their price objective on Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Friday, September 9th. Truist Financial lowered Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Finally, StockNews.com initiated coverage on Bausch Health Companies in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $10.60.

Bausch Health Companies Profile

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Further Reading

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCGet Rating).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.